VOR

Vor Biopharma Inc

Add to Watchlist

Advanced Chart

33.400

-0.4(-1.183%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

34.630

Open

34.120

VWAP

33.74

Vol

436.49K

Mkt Cap

228.49M

Low

33.200

Amount

14.73M

EV/EBITDA(TTM)

Total Shares

68.26M

30.67M

EV/OCF(TTM)

P/S(TTM)

Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-2.467

-52.56%

-4.000

-54.55%

-4.400

-45%

Estimates Revision

Stock Price

Go Down

-30.42%

In Past 3 Month

2 Analyst Rating

-13.17% Downside

Wall Street analysts forecast VOR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VOR is 29.00 USD with a low forecast of 3.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

-13.17% Downside

Current: 33.400

Low

3.00

Averages

29.00

High

55.00

-13.17% Downside

Current: 33.400

Low

3.00

Averages

29.00

High

55.00

Stifel

Stephen Willey

Hold

Buy

upgrade

$55

2025-09-23

Reason

Stifel

Stephen Willey

Price Target

$55

2025-09-23

upgrade

Hold

Buy

Reason

Stifel analyst Stephen Willey upgraded Vor Bio to Buy from Hold with a $55 price target. The firm notes that its multiple recent management meetings have turned it \"incrementally more-positive\" on telitacicept prospects across a diverse spectrum of autoimmune diseases, the analyst tells investors in a research note. Telitacicept, which already has three regulatory approvals and two planned regulatory submissions in China, is poised to potentially emerge as a best-in-class dual BAFF/APRIL antagonist, and the firm believes the requisite translation of this success to ongoing myasthenia gravis and aspiring global Phase 3 trials represents attractive biological/clinical and financial risk, the firm added.

H.C. Wainwright

Neutral

Buy

upgrade

2025-06-30

Reason

H.C. Wainwright

Price Target

2025-06-30

upgrade

Neutral

Buy

Reason

H.C. Wainwright upgraded Vor Bio to Buy from Neutral with a $3 price target. Vor's board has strategically strengthened the "three pillars" needed to potentially increase the odds to become a commercial company in 24-30 months from now, the analyst tells investors. The firm is "encouraged by the quick resurrection of the company by the board and the management" after the company entered into an exclusive license agreement with RemeGen Co. to develop and commercialize telitacicept, the analyst added.

Baird

Neutral

maintain

2025-06-27

Reason

Baird

Price Target

2025-06-27

maintain

Neutral

Reason

Baird raised the firm's price target on Vor Bio to $1 from 25c and keeps a Neutral rating on the shares. The firm updated its model following the licensing of Telitacicept from RemGen for autoimmune diseases.

Stifel

Stephen Willey

Buy -> Hold

downgrade

2025-05-09

Reason

Stifel

Stephen Willey

Price Target

2025-05-09

downgrade

Buy -> Hold

Reason

Stifel analyst Stephen Willey downgraded Vor Bio to Hold from Buy with a price target of 30c, down from $5, following the company's decision to explore a range of strategic alternatives in an effort to maximize shareholder value. The decision reflects a combination of both clinical data evaluated to date and the challenging financing environment currently characterizing the biotech sector, the analyst tells investors in a research note.

Citizens JMP

Outperform -> Market Perform

downgrade

2025-05-09

Reason

Citizens JMP

Price Target

2025-05-09

downgrade

Outperform -> Market Perform

Reason

Citizens JMP downgraded Vor Bio to Market Perform from Outperform without a price target. Vor is exploring strategic alternatives and ended all development programs based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the analyst tells investors in a research note. The firm views the shares as trading at fair value.

Baird

Outperform

Neutral

downgrade

$14

2025-05-09

Reason

Baird

Price Target

$14

2025-05-09

downgrade

Outperform

Neutral

Reason

Baird downgraded Vor Bio to Neutral from Outperform with a price target of 25c, down from $14, after the company announced plans to wind down its clinical and manufacturing operations, beginning immediately, and pivot to looking for strategic alternatives for the business. The update led Baird to downgrade the shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Vor Biopharma Inc (VOR.O) is -2.55, compared to its 5-year average forward P/E of -3.32. For a more detailed relative valuation and DCF analysis to assess Vor Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.32

Current PE

-2.55

Overvalued PE

0.56

Undervalued PE

-7.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.59

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.32

Undervalued EV/EBITDA

-5.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00